Influence of long-term continuous intravenous administration of pentoxifylline on endothelial-related coagulation in critically ill patients

Crit Care Med. 1996 Jun;24(6):940-6. doi: 10.1097/00003246-199606000-00011.

Abstract

Objective: To determine the influence of pentoxifylline on endothelial-associated coagulation.

Design: Prospective, randomized, placebo-controlled study.

Setting: A surgical intensive care unit of a university hospital.

Patients: Consecutive patients (n = 60) with trauma or sepsis secondary to major (nontrauma) surgery. All patients received controlled mechanical ventilation.

Interventions: According to a randomized sequence, the patients either received pentoxifylline continuously over 5 days (1.5 mg/kg/hr iv) (trauma-pentoxifylline group [n = 15], sepsis-pentoxifylline group [n=15] or saline solution as placebo (trauma-control group [n = 15], sepsis-control group [n = 15].

Measurements and main results: In addition to the standard coagulation screen, thrombomodulin, protein C, (free) protein S, and thrombin-antithrombin plasma concentrations were measured by enzyme-linked immunosorbent assays. Intensive care therapy, hemodynamics, and changes of Acute Physiology and Chronic Health Evaluation II score were comparable for pentoxifylline-treated and nontreated patients. An average dose of 2.5 g/day of pentoxifylline (range 2.2 to 2.9) was infused into the pentoxifylline-treated patients. At baseline, plasma thrombomodulin concentrations were higher in the septic patients than in the trauma patients. Thrombomodulin plasma concentrations increased significantly more in the control patients (trauma: from 38.9 +/- 10.5 to 59.9 +/- 10.1 ng/mL; sepsis: from 49.7 +/- 12.1 to 72.3 +/- 11.2 ng/mL) than in the pentoxifylline-treated patients (trauma: from 37.9 +/- 11.9 to 50.2 +/- 9.2 ng/mL; sepsis from 51.9 +/- 10.1 to 63.3 +/- 10.2). Starting from similar baseline values, protein C concentration increased significantly more in the sepsis-pentoxifylline patients (from 52.0 +/- 11.1% to 69.1 +/- 11.1%) than in the untreated septic patients (from 50.1 +/- 10.0% to 52.5 +/- 9.5%). There were no significant differences between the pentoxifylline-treated and nontreated groups for protein S and thrombin-antithrombin concentrations. Standard coagulation parameters (fibrinogen, activated partial thromboplastin time, antithrombin III) did not differ between these groups either.

Conclusions: Continuous intravenous administration of pentoxifylline for 5 days beneficially influenced the thrombomodulin/protein C/protein S system in both the trauma and septic patients.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Retracted Publication

MeSH terms

  • APACHE
  • Adult
  • Aged
  • Blood Coagulation / drug effects*
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / metabolism
  • Female
  • Hemodynamics / drug effects
  • Humans
  • Infusions, Intravenous
  • Injury Severity Score
  • Intensive Care Units
  • Male
  • Middle Aged
  • Pentoxifylline / administration & dosage
  • Pentoxifylline / therapeutic use*
  • Prospective Studies
  • Protein C / drug effects
  • Protein C / metabolism
  • Protein S / drug effects
  • Protein S / metabolism
  • Sepsis / blood
  • Sepsis / therapy*
  • Thrombomodulin / drug effects
  • Thrombomodulin / metabolism
  • Wounds and Injuries / blood
  • Wounds and Injuries / therapy*

Substances

  • Protein C
  • Protein S
  • Thrombomodulin
  • Pentoxifylline